Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (531-540 of 850) with videos related to

Pageof 85
Sort By:
European Urology|February 6, 2014
Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancerGiorgio Gandaglia, Maxine Sun, Jim C Hu, et al.
BJU International|February 11, 2012
Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysisJan Schmitges, Quoc-Dien Trinh, Maxine Sun, et al.
BJU International|September 30, 2010
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomyJochen Walz, Steven Joniau, Felix K Chun, et al.
The Journal of Urology|March 8, 2021
Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate CancerMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
British Journal of Cancer|September 9, 2020
EGFR as a stable marker of prostate cancer dissemination to bonesPaulina Nastały, Sara Stoupiec, Marta Popęda, et al.
International Journal of Cancer|October 12, 2020
Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancerKatharina Möller, Martina Kluth, Malik Ahmed, et al.
European Urology|December 24, 2013
Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsyGiovanni Lughezzani, Massimo Lazzeri, Alexander Haese, et al.
BMC Cancer|July 24, 2015
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionChristoph Burdelski, Devi Menan, Maria Christina Tsourlakis, et al.
Urologic Oncology|May 4, 2019
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomyPeter Klippenstein, Thorsten Schlomm, Gunhild von Amsberg, et al.
Clinical Genitourinary Cancer|April 14, 2021
Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER RegistriesMike Wenzel, Christoph Würnschimmel, Luigi Nocera, et al.
Pageof 85

Showing results (531-540 of 850) with videos related to

Sort By:
Pageof 85
European Urology|February 6, 2014
Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancerGiorgio Gandaglia, Maxine Sun, Jim C Hu, et al.
BJU International|February 11, 2012
Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysisJan Schmitges, Quoc-Dien Trinh, Maxine Sun, et al.
BJU International|September 30, 2010
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomyJochen Walz, Steven Joniau, Felix K Chun, et al.
The Journal of Urology|March 8, 2021
Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate CancerMike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, et al.
British Journal of Cancer|September 9, 2020
EGFR as a stable marker of prostate cancer dissemination to bonesPaulina Nastały, Sara Stoupiec, Marta Popęda, et al.
International Journal of Cancer|October 12, 2020
Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancerKatharina Möller, Martina Kluth, Malik Ahmed, et al.
European Urology|December 24, 2013
Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsyGiovanni Lughezzani, Massimo Lazzeri, Alexander Haese, et al.
BMC Cancer|July 24, 2015
The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletionChristoph Burdelski, Devi Menan, Maria Christina Tsourlakis, et al.
Urologic Oncology|May 4, 2019
Prostate cancer prognosis in men with other malignancies prior to radical prostatectomyPeter Klippenstein, Thorsten Schlomm, Gunhild von Amsberg, et al.
Clinical Genitourinary Cancer|April 14, 2021
Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER RegistriesMike Wenzel, Christoph Würnschimmel, Luigi Nocera, et al.
Pageof 85